Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Anteris Technologies Global Corp. Director's Dealing 2007

Jul 29, 2007

33869_rns_2007-07-29_2a997535-767b-49e6-bfc0-30d76c9c8bb0.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Innovative BioMedical Devices bioMD Limited ABN 35 088 221 078

Level 11, 225 St Georges Terrace Perth, Western Australia 6000 PO Box 7209, Cloisters Square Western Australia 6850

Telephone (08) 9262 6777 Facsimile (08) 9322 3433 www.biomd.com.au

==> picture [50 x 33] intentionally omitted <==

ANNOUNCEMENT TO THE AUSTRALIAN STOCK EXCHANGE

1 of 2 pages

30 July 2007

Company Announcements Office Australian Stock Exchange Limited 10[th] Floor, 20 Bond Street SYDNEY NSW 2000

Dear Sir/Madam

Re: Appendix 3Y – Change in Director’s Interest Notice

The Directors of bioMD Ltd wish to advise of a change to the notifiable interests of a director, in accordance with Listing Rule 3.19A.1 and section 205G of the Corporations Act.

Please refer to the ‘Appendix 3Y’ attached for details of change in director’s holding.

Yours faithfully

==> picture [114 x 85] intentionally omitted <==

CAROLINE L BENTLEY Company Secretary

APPENDIX 3Y

CHANGE OF DIRECTOR’S INTEREST NOTICE

Name of Entity: bioMD Limited ABN: 35 055 221 078

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director: Robert Towner

Date of last notice: 14 June 2007

PART 1 – Change of director's relevant interests in securities

Direct or indirect interest: Direct / Indirect Nature of indirect interest: Mr Towner is a director of a company holding BOD Date of change: 24 July 2007 No. of securities held prior to change: Ordinary shares Direct: 150,000 Indirect: 10,501,080 Class: Listed ordinary shares (BOD) Number acquired: 50,000 Number disposed: N/A Value/Consideration: $7,000 No. of securities held after change: Ordinary shares Direct: 150,000 Indirect: 10,551,080 Nature of the change: On-market purchase

PART 2 – Change of director’s interests in contracts

Details of contract: None Applicable Nature of interest: Name of registered holder: (if issued securities) No. and class of securities to which interest relates: Interest acquired: Interest disposed: Value/Consideration: Interest after change: